Ajax loader

Types 

Types 

Orientation 

Orientation 

Can't find what you're looking for?

 

Be sure to Sign in to see all available content.

 

If you don't have an account, Register here.

Ebola Epidemic 

RTR4CV9E 
Experimental Vaccines - 05 Nov 2014 
Canada announced new funding on Monday for clinical trials into an Ebola vaccine, and to create a stockpile of the vaccine and experimental treatments for use in the event the deadly disease reaches the country.

Speaking at the laboratory in Winnipeg, Manitoba, where scientists developed an experimental Ebola treatment, ZMAb, Health Minister Rona Ambrose said Ottawa was committing C$23.5 million ($20.7 million) for research and development of Ebola vaccines and treatments.

"These funds announced today will help support Ebola vaccine clinical trials and to create a stockpile of the vaccine and monochlonal antibody treatments of Ebola for use in Canada in the event of a case of Ebola, and to assist in the outbreak response in West Africa," Ambrose said.

No cases of Ebola have been reported in Canada, but Ottawa announced on Friday it will stop issuing visas to people from the three West African nations where Ebola is widespread. 
HEALTH-EBOLA/VACCINES-SWISS
RTR4CSBJ 
November 04, 2014 
A nurse holds a syringe containing an experimental Ebola virus vaccine during a media visit at the Lausanne... 
Lausanne, Switzerland 
A nurse holds a syringe containing an experimental Ebola vaccine during a media visit at the CHUV in... 
A nurse holds a syringe containing an experimental Ebola virus vaccine during a media visit at the Lausanne University Hospital (CHUV) in Lausanne November 4, 2014. A trial is being conducted with a vaccine from GlaxoSmithKline among 120 healthy volunteers with support from the World Health Organization (WHO). The participants will be monitored for six months to determine both the safety and efficiency of the vaccine in the fight against the worst outbreak of Ebola on record which has killed nearly 5,000 people. REUTERS/Denis Balibouse (SWITZERLAND - Tags: HEALTH SCIENCE TECHNOLOGY)
HEALTH-EBOLA/VACCINES-SWISS
RTR4CSC4 
November 04, 2014 
A nurse prepares a syringe containing an experimental Ebola virus vaccine next to a volunteer called... 
Lausanne, Switzerland 
A nurse prepares syringe containing an experimental Ebola vaccine for volunteer during a media visit... 
A nurse prepares a syringe containing an experimental Ebola virus vaccine next to a volunteer called Trina Helderman (L) during a media visit at the Lausanne University Hospital (CHUV) in Lausanne November 4, 2014. A trial is being conducted with a vaccine from GlaxoSmithKline among 120 healthy volunteers with support from the World Health Organization (WHO). The participants will be monitored for six months to determine both the safety and efficiency of the vaccine in the fight against the worst outbreak of Ebola on record which has killed nearly 5,000 people. REUTERS/Denis Balibouse (SWITZERLAND - Tags: HEALTH SCIENCE TECHNOLOGY TPX IMAGES OF THE DAY)
HEALTH-EBOLA/VACCINE
RTR46MHV 
September 17, 2014 
Volunteer Ruth Atkins has blood taken before receiving an injection of the Ebola vaccine at the Oxford... 
Oxford, United Kingdom 
Volunteer Ruth Atkins has blood taken before receiving an injection of the Ebola vaccine at the Oxford... 
Volunteer Ruth Atkins has blood taken before receiving an injection of the Ebola vaccine at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool (BRITAIN - Tags: HEALTH SCIENCE TECHNOLOGY) 
HEALTH-EBOLA/VACCINE
RTR46MIN 
September 17, 2014 
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds... 
Oxford, United Kingdom 
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds... 
Professor Adrian Hill, Director of the Jenner Institute, and Chief Investigator of the trials, holds a phial containing the Ebola vaccine at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool (BRITAIN - Tags: HEALTH SCIENCE TECHNOLOGY TPX IMAGES OF THE DAY) 
HEALTH-EBOLA/VACCINE
RTR46MJ9 
September 17, 2014 
Volunteer Ruth Atkins receives an injection of the Ebola vaccine, at the Oxford Vaccine Group Centre... 
Oxford, United Kingdom 
Volunteer Ruth Atkins receives an injection of the ebola vaccine at the Oxford Vaccine Group Centre for... 
Volunteer Ruth Atkins receives an injection of the Ebola vaccine, at the Oxford Vaccine Group Centre for Clinical Vaccinology and Tropical Medicine (CCVTM) in Oxford, southern England September 17, 2014. The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. REUTERS/Steve Parsons/Pool (BRITAIN - Tags: HEALTH SCIENCE TECHNOLOGY) 
HEALTH-EBOLA/DRUGS
RTR44VEX 
September 04, 2014 
A participant reads a document on districts affected by Ebola in Guinea, on a screen at the opening of... 
Geneva, Switzerland 
A participant reads a document on districts affected by Ebola in Guinea, at the opening of a consultation... 
A participant reads a document on districts affected by Ebola in Guinea, on a screen at the opening of a consultation of international experts on potential Ebola therapies and vaccines in Geneva September 4, 2014. On September 4 and 5, the World Health Organization (WHO) brings together 200 key experts to discuss experimental therapies and vaccines with potential to treat or prevent the Ebola virus disease. REUTERS/Denis Balibouse (SWITZERLAND - Tags: POLITICS HEALTH) 
HEALTH-EBOLA/DRUGS
RTR44VF1 
September 04, 2014 
A document is pictured at the opening of a consultation of international experts on potential Ebola therapies... 
Geneva, Switzerland 
A document is pictured at the opening of a consultation of international experts on potential Ebola therapies... 
A document is pictured at the opening of a consultation of international experts on potential Ebola therapies and vaccines in Geneva September 4, 2014. On September 4 and 5, the World Health Organization (WHO) brings together 200 key experts to discuss experimental therapies and vaccines with potential to treat or prevent the Ebola virus disease. REUTERS/Denis Balibouse (SWITZERLAND - Tags: POLITICS HEALTH) 
HEALTH-EBOLA/GERMANY-COMPANY
RTR42FWI 
August 14, 2014 
A laboratory technican of the company Icon Genetics prepares proteines from Tobacco plants (Nicotiana... 
Berlin, Germany 
A laboratory technican of the company Icon Genetics prepares proteines from Tobacco plants (Nicotiana... 
A laboratory technican of the company Icon Genetics prepares proteines from Tobacco plants (Nicotiana benthamiana) for weighing in a laboratory in Halle, August 14, 2014. Icon Genetics develop a technology to mass produce Ebola vaccine with the help of tobacco plants. REUTERS/Axel Schmidt (GERMANY - Tags: HEALTH SCIENCE TECHNOLOGY)
HEALTH-EBOLA/GERMANY-COMPANY
RTR42FWM 
August 14, 2014 
Laboratory technicans of the company Icon Genetics prepare proteines from Tobacco plants (Nicotiana benthamiana)... 
Berlin, Germany 
Laboratory technicans of the company Icon Genetics prepare proteines from Tobacco plants (Nicotiana benthamiana)... 
Laboratory technicans of the company Icon Genetics prepare proteines from Tobacco plants (Nicotiana benthamiana) for weighing in a laboratory in Halle, August 14, 2014. Icon Genetics develop a technology to mass produce Ebola vaccine with the help of tobacco plants. REUTERS/Axel Schmidt (GERMANY - Tags: HEALTH SCIENCE TECHNOLOGY)
HEALTH-EBOLA/GERMANY-COMPANY
RTR42FWN 
August 14, 2014 
A laboratory technican of the company Icon Genetics prepares proteines from Tobacco plants (Nicotiana... 
Berlin, Germany 
A laboratory technican of the company Icon Genetics prepares proteines from Tobacco plants (Nicotiana... 
A laboratory technican of the company Icon Genetics prepares proteines from Tobacco plants (Nicotiana benthamiana) for weighing in a laboratory in Halle, August 14, 2014. Icon Genetics develop a technology to mass produce Ebola vaccine with the help of tobacco plants. REUTERS/Axel Schmidt (GERMANY - Tags: HEALTH SCIENCE TECHNOLOGY)
Display 
Items per page 
Page 
of 1